homepage-top-section

Erasca’s ERAS-007 is currently being evaluated alone or in combination with different inhibitors to upstream MAPK pathway nodes as part of the MAPKlamp strategy. Under the collaboration, Lilly

An autologous TCR-T cell treatment, NTLA-5001 is intended to target the Wilms’ Tumor (WT1) antigen, which is highly expressed in AML and several other hematologic and solid tumours.

A drug-free nasal spray, Bentrio is designed for personal protection against airborne viruses and allergens. It forms a protective gel layer on the nasal mucosa upon application into

As per the terms of the updated and restated deal, Helsinn will obtain an exclusive license for infigratinib commercialisation in the US. The company will also develop, produce,

Co-led by Canaan Partners and Red Tree Venture Capital, the financing round included significant investment from Johnson & Johnson Innovation – JJDC. SV Health Investors and Novo Holdings

The regulatory agency issued a complete response letter (CRL) to the company’s New Drug Application (NDA) for lenacapavir mentioning Chemistry Manufacturing and Controls (CMC) issues related to its

Jointly developed and commercialised by Pharmacyclics, Imbruvica (ibrutinib) is a once-daily oral medication that blocks the Bruton’s tyrosine kinase (BTK) protein. The sNDA seeks approval for the drug

Keytruda is Merck’s an anti-programmed death receptor-1 (PD-1) therapy that increases the ability of the immune system in body for detecting and fighting tumour cells. It is a

The investigational, phosphodiesterase 4B (PDE4B) inhibitor, BI 1015550 has the potential to address pulmonary fibrosis as well as inflammation linked to progressive fibrosing interstitial lung diseases (ILDs). Pulmonary